open access

Vol 72, No 5 (2022)
Review paper
Published online: 2022-10-19
Get Citation

Combined radiotherapy and chemotherapy

Monika Rucińska1
DOI: 10.5603/NJO.2022.0051
·
Nowotwory. Journal of Oncology 2022;72(5):319-325.
Affiliations
  1. Department of Oncology, Collegium Medicum, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland

open access

Vol 72, No 5 (2022)
Radiotherapy in the combined treatment
Published online: 2022-10-19

Abstract

Combined radiotherapy and chemotherapy is a standard procedure in radical treatment of many cancers. The objective of chemoradiotherapy is to increase loco-regional control, to reduce the risk of distant metastases and to prolong survival, and thus to improve treatment efficiency with less mutilating therapies. Concurrent chemoradiotherapy, however, is more toxic than chemotherapy and radiotherapy alone or sequential application of these methods. Optimalisation of combined treatment requires further research. New possibilities arise with inclusion of targeted treatment and immu­notherapy in classical chemoradiotherapy.

Abstract

Combined radiotherapy and chemotherapy is a standard procedure in radical treatment of many cancers. The objective of chemoradiotherapy is to increase loco-regional control, to reduce the risk of distant metastases and to prolong survival, and thus to improve treatment efficiency with less mutilating therapies. Concurrent chemoradiotherapy, however, is more toxic than chemotherapy and radiotherapy alone or sequential application of these methods. Optimalisation of combined treatment requires further research. New possibilities arise with inclusion of targeted treatment and immu­notherapy in classical chemoradiotherapy.

Get Citation

Keywords

radiotherapy; chemotherapy; combined treatment

About this article
Title

Combined radiotherapy and chemotherapy

Journal

Nowotwory. Journal of Oncology

Issue

Vol 72, No 5 (2022)

Article type

Review paper

Pages

319-325

Published online

2022-10-19

Page views

234

Article views/downloads

50

DOI

10.5603/NJO.2022.0051

Bibliographic record

Nowotwory. Journal of Oncology 2022;72(5):319-325.

Keywords

radiotherapy
chemotherapy
combined treatment

Authors

Monika Rucińska

References (80)
  1. https://www.nccn.org/professionals/physician_gls/pdf/.
  2. https://www.esmo.org/guidelines.
  3. https://www.asco.org/practice-patients/guidelines.
  4. Willey C, Yang EH, Bonner J. Interaction of Chemotherapy and Radiation. Clinical Radiation Oncology. 2016: 63–79.e4.
  5. Rallis KS, Lai Yau THo, Sideris M. Chemoradiotherapy in Cancer Treatment: Rationale and Clinical Applications. Anticancer Res. 2021; 41(1): 1–7.
  6. HEIDELBERGER C, CHAUDHURI NK, DANNEBERG P, et al. Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature. 1957; 179(4561): 663–666.
  7. Rich TA, Shepard RC, Mosley ST. Four decades of continuing innovation with fluorouracil: current and future approaches to fluorouracil chemoradiation therapy. J Clin Oncol. 2004; 22(11): 2214–2232.
  8. Steel GG, Peckham M. Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivity. Int J Radiat Oncol Biol Phys. 1979; 5(1): 85–91.
  9. Kouvaris JR, Kouloulias VE, Vlahos LJ. Amifostine: the first selective-target and broad-spectrum radioprotector. Oncologist. 2007; 12(6): 738–747.
  10. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm--general principles. Nat Clin Pract Oncol. 2007; 4(2): 86–100.
  11. Morgan MA, Parsels LA, Maybaum J, et al. Improving the efficacy of chemoradiation with targeted agents. Cancer Discov. 2014; 4(3): 280–291.
  12. Bentzen SM, Harari PM, Bernier J. Exploitable mechanisms for combining drugs with radiation: concepts, achievements and future directions. Nat Clin Pract Oncol. 2007; 4(3): 172–180.
  13. CHOY H. Chemotherapy and irradiation interaction. Seminars in Oncology. 2003; 30(4 Suppl 9): 3–10.
  14. Choy H, Rodriguez F, Koester S, et al. Investigation of taxol as a potential radiation sensitizer. Cancer. 1993; 71(11): 3774–3778, doi: 10.1002/1097-0142(19930601)71:11<3774::aid-cncr2820711147>3.0.co;2-0.
  15. McGinn CJ, Kinsella TJ. The experimental and clinical rationale for the use of S-phase-specific radiosensitizers to overcome tumor cell repopulation. Semin Oncol. 1992; 19(4 Suppl 11): 21–28.
  16. Milas L, Hunter N, Mason KA, et al. Tumor reoxygenation as a mechanism of taxol-induced enhancement of tumor radioresponse. Acta Oncol. 1995; 34(3): 409–412.
  17. Hentosh P. Induction and repair of DNA damage in gamma-irradiated human lymphoblasts: irradiation in the presence and absence of misonidazole. Radiat Res. 1988; 115(3): 436–447.
  18. Seiwert TY, Salama JK, Vokes EE. The concurrent chemoradiation paradigm--general principles. Nat Clin Pract Oncol. 2007; 4(2): 86–100.
  19. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med. 1994; 331(8): 502–507.
  20. Heinrich MC, Hoatlin ME, Zigler AJ, et al. DNA cross-linked-induced G2/M arrest in group C Fanconi anemia lymphoblasts reflects normal checkpoint function. Blood. 1998; 91: 275–287.
  21. De Ridder M, Van Esch G, Engels B, et al. Hypoxic tumor cell radiosensitization: role of the iNOS/NO pathway. Bull Cancer. 2008; 95(3): 282–291.
  22. Sugiyama K, Shimizu M, Akiyama T, et al. UCN-01 selectively enhances mitomycin C cytotoxicity in p53 defective cells which is mediated through S and/or G2 checkpoint abrogation. International Journal of Cancer. 2000; 85(5): 703–709, doi: 10.1002/(sici)1097-0215(20000301)85:5<703::aid-ijc17>3.0.co;2-7.
  23. Budach W, Paulsen F, Welz S, et al. Mitomycin C in combination with radiotherapy as a potent inhibitor of tumour cell repopulation in a human squamous cell carcinoma. Br J Cancer. 2002; 86(3): 470–476.
  24. Stupp R, Hegi ME, Gilbert MR, et al. Chemoradiotherapy in malignant glioma: standard of care and future directions. J Clin Oncol. 2007; 25(26): 4127–4136.
  25. Palanichamy K, Chakravarti A. Combining drugs and radiotherapy: from the bench to the bedside. Curr Opin Neurol. 2009; 22(6): 625–632.
  26. Howle J, Gale G. CIS-dichlorodiammineplatinum (II). Biochemical Pharmacology. 1970; 19(10): 2757–2762.
  27. Taylor D, Tew K, Jones J. Effects of cis-dichlorodiammine platinum (II) on DNA synthesis in kidney and other tissues of normal and tumour-bearing rats. Eur J Cancer (1965). 1976; 12(4): 249–254.
  28. Corda Y, Job C, Anin MF, et al. Transcription by eucaryotic and procaryotic RNA polymerases of DNA modified at a d(GG) or a d(AG) site by the antitumor drug cis-diamminedichloroplatinum(II). Biochemistry. 1991; 30(1): 222–230.
  29. Vokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: rationale and clinical experience in patients with solid tumors. J Clin Oncol. 1990; 8(5): 911–934.
  30. Hennequin C, Favaudon V. Biological basis for chemo-radiotherapy interactions. Eur J Cancer. 2002; 38(2): 223–230.
  31. Amorino G, Freeman M, Carbone D, et al. Radiopotentiation by the oral platinum agent, JM216: role of repair inhibition. Int J Radiat Oncol Biol Phys. 1999; 44(2): 399–405.
  32. Wilson GD, Bentzen SM, Harari PM. Biologic basis for combining drugs with radiation. Semin Radiat Oncol. 2006; 16(1): 2–9.
  33. Perez EA. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Mol Cancer Ther. 2009; 8(8): 2086–2095.
  34. Schiff PB, Horwitz SB. Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci U S A. 1980; 77(3): 1561–1565.
  35. Creane M, Seymour CB, Colucci S, et al. Radiobiological effects of docetaxel (Taxotere): a potential radiation sensitizer. Int J Radiat Biol. 1999; 75(6): 731–737.
  36. Bristow RG, Hill RP. Molecular and cellular basis of radiotherapy. In: Tannock IF, Hill RP. ed. The Basic Science of Oncology. McGraw-Hill, Montreal 1991: 295–321.
  37. Lloyd RV, Duling DR, Rumyantseva GV, et al. Microsomal reduction of 3-amino-1,2,4-benzotriazine 1,4-dioxide to a free radical. Mol Pharmacol. 1991; 40(3): 440–445.
  38. Nigro ND, Vaitkevicius VK, Considine B. Combined therapy for cancer of the anal canal: a preliminary report. Dis Colon Rectum. 1974; 17(3): 354–356.
  39. Sischy B, Doggett RL, Krall JM, et al. Definitive irradiation and chemotherapy for radiosensitization in management of anal carcinoma: Interim report on Radiation Therapy Oncology Group study no. 8314. J Natl Cancer Inst. 1989; 81: 850–856.
  40. Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol. 1997; 15(5): 2040–2049.
  41. Gunderson LL, Winter KA, Ajani JA, et al. Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil/mitomycin versus fluorouracil/cisplatin. J Clin Oncol. 2012; 30(35): 4344–4351.
  42. Kachnic LA, Winter K, Myerson RJ, et al. RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. Int J Radiat Oncol Biol Phys. 2013; 86(1): 27–33.
  43. Northover J, Glynne-Jones R, Sebag-Montefiore D, et al. Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I). Br J Cancer. 2010; 102(7): 1123–1128.
  44. Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol. 1996; 14(9): 2527–2539.
  45. Prasad RN, Elson J, Kharofa J. The effect of dose escalation for large squamous cell carcinomas of the anal canal. Clin Transl Oncol. 2018; 20(10): 1314–1320.
  46. Boulis-Wassif S, Gerard A, Loygue J, et al. Final results of a randomized trial on the treatment of rectal cancer with preoperative radiotherapy alone or in combination with 5-fluorouracil, followed by radical surgery trial of the european organization on research and treatment of cancer gastrointestinal tract cancer cooperative group. Cancer. 1984; 53(9): 1811–1818, doi: 10.1002/1097-0142(19840501)53:9<1811::aid-cncr2820530902>3.0.co;2-h.
  47. Bosset JF, Collette L, Calais G, et al. EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006; 355(11): 1114–1123.
  48. Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006; 93(10): 1215–1223.
  49. Gérard JP, Conroy T, Bonnetain F, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006; 24(28): 4620–4625.
  50. Ceelen W, Fierens K, Van Nieuwenhove Y, et al. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer: a systematic review and meta-analysis. Int J Cancer. 2009; 124(12): 2966–2972.
  51. Sauer R, Becker H, Hohenberger W, et al. German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004; 351(17): 1731–1740.
  52. Herskovic A, Martz K, al-Sarraf M, et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med. 1992; 326(24): 1593–1598.
  53. Cooper JS, Guo MD, Herskovic A, et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA. 1999; 281(17): 1623–1627.
  54. Hulshof MC, Geijsen ED, Rozema T, et al. Randomized Study on Dose Escalation in Definitive Chemoradiation for Patients With Locally Advanced Esophageal Cancer (ARTDECO Study). J Clin Oncol. 2021; 39(25): 2816–2824.
  55. Crehange G, M'vondo C, Bertaut A, et al. Exclusive Chemoradiotherapy With or Without Radiation Dose Escalation in Esophageal Cancer: Multicenter Phase 2/3 Randomized Trial CONCORDE (PRODIGE-26). International Journal of Radiation Oncology*Biology*Physics. 2021; 111(3): S5.
  56. Wong R, Malthaner R. Combined chemotherapy and radiotherapy (without surgery) compared with radiotherapy alone in localized carcinoma of the esophagus. Cochrane Database Syst Rev. 2006(1): CD002092.
  57. Tepper J, Krasna MJ, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008; 26(7): 1086–1092.
  58. van Hagen P, Hulshof MC, van Lanschot JJB, et al. CROSS Group. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012; 366(22): 2074–2084.
  59. Oppedijk V, van der Gaast A, van Lanschot JJB, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014; 32(5): 385–391.
  60. Gupta S, Maheshwari A, Parab P, et al. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial. J Clin Oncol. 2018; 36(16): 1548–1555.
  61. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol. 1999; 17(5): 1339–1348.
  62. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999; 340(15): 1144–1153.
  63. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med. 1999; 340(15): 1154–1161.
  64. Peters WA, Liu PY, Barrett RJ, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol. 2000; 18(8): 1606–1613.
  65. McCormack M, Kadalayil L, Hackshaw A, et al. A phase II study of weekly neoadjuvant chemotherapy followed by radical chemoradiation for locally advanced cervical cancer. Br J Cancer. 2013; 108(12): 2464–2469.
  66. Tripathi A, Rawat S. Comparative Study of Neoadjuvant Chemotherapy Followed by Definitive Chemoradiotherapy Versus Definitive Chemoradiotherapy Alone in Locally Advanced Carcinoma of Cervix. J Obstet Gynaecol India. 2019; 69(6): 546–552.
  67. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med. 1990; 323(14): 940–945.
  68. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst. 1995; 87(3): 198–205.
  69. Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in nonresectable non-small-cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst. 1991; 83(6): 417–423.
  70. O'Rourke N, Roqué I Figuls M, Farré Bernadó N, et al. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2010(6): CD002140.
  71. Rowell NP, O'rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev. 2004(4): CD002140.
  72. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28(13): 2181–2190.
  73. Ghate K, Brennan K, Karim S, et al. Concurrent chemoradiotherapy for bladder cancer: Practice patterns and outcomes in the general population. Radiother Oncol. 2018; 127(1): 136–142.
  74. Haque W, Verma V, Butler EB, et al. Radical Cystectomy Chemoradiation for Muscle-invasive Bladder Cancer: Impact of Treatment Facility and Sociodemographics. Anticancer Res. 2017; 37(10): 5603–5608.
  75. Ritch CR, Balise R, Prakash NS, et al. Propensity matched comparative analysis of survival following chemoradiation or radical cystectomy for muscle-invasive bladder cancer. BJU Int. 2018; 121(5): 745–751.
  76. Al-Sarraf M, LeBlanc M, Giri PG, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099. J Clin Oncol. 1998; 16(4): 1310–1317.
  77. Pignon JP, le Maître A, Maillard E, et al. MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009; 92(1): 4–14.
  78. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003; 349(22): 2091–2098.
  79. Bernier J, Domenge C, Ozsahin M, et al. European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004; 350(19): 1945–1952.
  80. Cooper JS, Pajak TF, Forastiere AA, et al. Radiation Therapy Oncology Group 9501/Intergroup. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004; 350(19): 1937–1944.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest VM Media sp. z o.o. VM Group sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl